Position Paper: Differential Features of Beta- Adrenoreceptor Blocking Drugs for Therapy

  • Denis G. McDevitt


More than 30 years ago, in studying the effects of six sympathomimetic amines on a variety of effector systems, Ahlquist (1) classified adrenore-ceptors into two distinct types: alpha-receptors, whose stimulation produces excitatory responses, and beta-receptors, whose activation results in in-hibitory responses plus cardiac stimulation. Beta- receptors have been further classified into betai-receptors (which occur chiefly in the heart) and beta2-receptors (which occur elsewhere) (2). The distribution of adrenoreceptors is shown in Table 1, although it now appears that more than one type of beta-receptor may 1, although it now appears that more than one type of beta-receptor may be present both in the heart and in the lung (3).


Blocking Drug Renin Release Partial Agonist Activity Ceptor Antagonist Plasma Free Fatty Acid Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ahlquist RP (1948) A study of the adrenotropic receptors. Am J Physiol (Lond) 153: 586 - 600Google Scholar
  2. 2.
    Lands AM, Luduena FP, Buzzo HJ (1967) Differentiation of receptor systems responsive to isoproterenol. Life Sci 6: 2241–2249PubMedCrossRefGoogle Scholar
  3. 3.
    Barnett DB, Rubb EL, Nohorski SR (1977) Direct evidence for two types of beta-adrenoceptor binding site in lung tissue. Nature 273: 166–168CrossRefGoogle Scholar
  4. 4.
    Powell CB, Slater IH (1958) Blocking of inhibitory adrenergic receptors by a dichloro analog of isoproterenol. Pharmacol Exp Ther 122: 480–488Google Scholar
  5. 5.
    Barrett AM (1973) Beta-adrenoceptive antagonists: In: Hamer J (ed) Recent advances in cardiology. Churchill Livingstone, Edinburgh and London, p 289Google Scholar
  6. 6.
    Morales-Aguilera A, Vaughan-Williams EM (1965) The effects on cardiac muscle of ß-receptor antagonists in relation to their activity as locak anaesthetics. Br J Pharmacol 24: 332–338Google Scholar
  7. 7.
    Coltart DJ, Meldrum SJ (1970) The effect of pro-pranolol on the human and canine transmembrane action potential. Br J Pharmacol 40: 148 PGoogle Scholar
  8. 8.
    McDevitt DG, Brown HC, Carruthers SG, Shanks RG (1977) Observations on the influence of intrinsic sympathomimetic activity and cardioselectivity on ß-adrenoceptor blockade in man. Clin Pharmacol Ther 21: 556–566PubMedGoogle Scholar
  9. 9.
    Choquet Y, Capone RJ, Mason DT, Amsterdam EA, Zelis R (1972) Comparison of the beta-adren- ergic blocking properties and negative inotropic ef¬fects of Oxprenolol and propranolol in patients. Am J Cardiol 29: 257CrossRefGoogle Scholar
  10. 10.
    Gibson (1977) Pharmacodynamic properties of ß- adrenoceptor blocking drugs in man. In: Avery GS (ed) Drug Treatment: Principles and Practice of Clinical Pharmacology and Therapeutics. Publishing Services Group, Acton, Mass.Google Scholar
  11. 11.
    Franciosa JA, Johnson SM, Tobian LJ (1980) Haemodynamic effects of oxprenolol and propranolol in hypertension. Clin Pharmacol Ther 26: 676–681Google Scholar
  12. 12.
    Connolly CK, Batten JC (1970) Comparison of the effect of alprenolol and propranolol on specific airway conductance in asthmatic subjects. Br Med J 2: 515–516PubMedCrossRefGoogle Scholar
  13. 13.
    Oh VMS, Kaye CM, Warrington SJ, Taylor EA, Wadsworth J (1978) Studies of cardioselectivity and partial agonist activity in ß-andrenoceptor blockade comparing effects on heart rate and peak expiratory flow rate. Br J Clin Pharmacol 5: 107–120PubMedGoogle Scholar
  14. 14.
    McDevitt DG (1978) ß-adrenoceptor antagonists and respiratory function. Br J Clin Pharmacol 5: 97–99PubMedGoogle Scholar
  15. 15.
    Christenson CC, Boye NP, Erikson H, Hansen G (1978) Influence of pindolol ( Visken) on respiratory function. Eur J Pharmacol 13: 9–12Google Scholar
  16. 16.
    Marshall AJ, Roberts CJC, Barritt DW (1976) Raynaud’s phenomenon as side-effect of ß-blockers in hypertension. Br Med J 1: 1498–1499PubMedCrossRefGoogle Scholar
  17. 17.
    McNeill RS (1964) Effect of a ß-adrenergic blocking agent, propranolol, on asthmatics. Lancet 2: 1101–1102PubMedCrossRefGoogle Scholar
  18. 18.
    Powles R, Shinebourne E, Hamer J (1969) Selective cardiac sympathetic blockade as an adjunct to bronchodilator therapy. Thorax 24: 616–618PubMedCrossRefGoogle Scholar
  19. 19.
    Lertora JJL, Mark AL, Johannsen UJ, Wilson WR, Abboud FM (1975) Selective ß-adrenoceptor blockade with oral practolol in man. A dose related phenomenon. J Clin Invest 56: 719–24PubMedCrossRefGoogle Scholar
  20. 20.
    Chang LCT (1971) Use of practolol in asthmatics: A plea for caution. Lancet 2: 321PubMedCrossRefGoogle Scholar
  21. 21.
    Formgren H (1976) The effect of metoprolol and practolol on lung function and blood pressure in hypertensive asthmatics. Br J Clin Pharmacol 3: 1007–1014Google Scholar
  22. 22.
    Davidson N McD, Corrall RJM, Shaw TRD, French EB (1976) Observations in man of hypogly- caemia during selective and non-selective beta- blockade. Scot Med J 22: 69–72Google Scholar
  23. 23.
    Deacon SP, Barnet D (1976) Comparison of atenolol and propranolol during insulin-induced hypoglycaemia. Br Med J 2: 272–273PubMedCrossRefGoogle Scholar
  24. 24.
    Laragh JH (1973) Vasoconstriction-volume analysis for understanding and treating hypertension: The use of renin and aldosterone profiles. Am J Med 55: 261–274PubMedCrossRefGoogle Scholar
  25. 25.
    Stokes GS, Weber MS, Thornell IR (1974) ß-blockers and plasma renin activity in hypertension. Br Med J 1: 60–62PubMedCrossRefGoogle Scholar
  26. 26.
    Hollifield JW, Sherman K, Vander Zwagg R, Shand DG (1976) Proposed mechanism of propranolol’s antihypertensive effect in essential hypertension. N Eng J Med 295: 68–73CrossRefGoogle Scholar
  27. 27.
    Shand DG (1977) Pharmacokinetic properties of the ß-adrenoceptor blocking drugs. In: Avery GS (ed) Cardiovascular drugs, Adis Press, Sydney (ß- Adrenoceptor blocking drugs, Vol 2, pp 41–54 )Google Scholar
  28. 28.
    McDevitt DG (1977) The assessment of ß-adrenoceptor blocking drugs in man. Br J Clin Pharmacol 4: 413–425PubMedGoogle Scholar
  29. 29.
    Salem SAM, McDevitt DG (1980) Central effects of atenolol in man. Clin Pharmacol Ther 27: 283Google Scholar

Copyright information

© Springer-Verlag New York Inc. 1981

Authors and Affiliations

  • Denis G. McDevitt

There are no affiliations available

Personalised recommendations